Esperion Therapeutics, Inc. - COM (ESPR)

CUSIP: 29664W105

Q4 2017 13F Holders as of 31 Dec 2017

Type / Class
Equity / COM
Shares outstanding
258,506,508
Total 13F shares
24,011,278
Share change
+102,949
Total reported value
$1,580,908,389
Put/Call ratio
106%
Price per share
$65.84
Number of holders
163
Value change
+$28,478,384
Number of buys
83
Number of sells
78

Quarterly Holders Quick Answers

What is CUSIP 29664W105?
CUSIP 29664W105 identifies ESPR - Esperion Therapeutics, Inc. - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Top shareholders of ESPR - Esperion Therapeutics, Inc. - COM (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
Meditor Group Ltd
13F
Company
0.89%
2,294,935
$115,022,000 30 Sep 2017
13F
Pentwater Capital Management LP
13F
Company
0.87%
2,243,200
$112,429,000 30 Sep 2017
13F
BB BIOTECH AG
13F
Company
0.81%
2,097,964
$105,150,000 30 Sep 2017
13F
BlackRock Finance, Inc.
13F
Company
0.59%
1,521,674
$76,267,000 30 Sep 2017
13F
FMR LLC
13F
Company
0.52%
1,342,888
$67,306,000 30 Sep 2017
13F
STATE STREET CORP
13F
Company
0.49%
1,260,414
$63,166,000 30 Sep 2017
13F
CREDIT SUISSE AG/
13F
Company
0.41%
1,064,038
$53,330,000 30 Sep 2017
13F
VANGUARD GROUP INC
13F
Company
0.34%
880,323
$44,121,000 30 Sep 2017
13F
Aisling Capital LLC
13F
Company
0.32%
837,125
$41,957,000 30 Sep 2017
13F
DISCOVERY CAPITAL MANAGEMENT, LLC / CT
13F
Company
0.3%
783,059
$39,247,000 30 Sep 2017
13F
PINNACLE ASSOCIATES LTD
13F
Company
0.28%
717,813
$35,977,000 30 Sep 2017
13F
WASATCH ADVISORS LP
13F
Company
0.28%
713,404
$35,756,000 30 Sep 2017
13F
NORTHERN TRUST CORP
13F
Company
0.22%
577,917
$28,965,000 30 Sep 2017
13F
PFM Health Sciences, LP
13F
Company
0.21%
548,682
$27,500,000 30 Sep 2017
13F
Boxer Capital, LLC
13F
Company
0.19%
500,000
$25,060,000 30 Sep 2017
13F
BALYASNY ASSET MANAGEMENT L.P.
13F
Company
0.15%
393,150
$19,705,000 30 Sep 2017
13F
Rhenman & Partners Asset Management AB
13F
Company
0.12%
311,803
$15,628,000 30 Sep 2017
13F
PICTET ASSET MANAGEMENT LTD
13F
Company
0.12%
306,455
$15,360,000 30 Sep 2017
13F
PEREGRINE CAPITAL MANAGEMENT LLC
13F
Company
0.11%
290,027
$14,536,000 30 Sep 2017
13F
Aviva Holdings Ltd.
13F
Company
0.11%
289,100
$14,490,000 30 Sep 2017
13F
GOLDMAN SACHS GROUP INC
13F
Company
0.1%
259,096
$12,986,000 30 Sep 2017
13F
CAISSE DE DEPOT ET PLACEMENT DU QUEBEC
13F
Individual
0.1%
250,000
$12,583,000 30 Sep 2017
13F
LORD, ABBETT & CO. LLC
13F
Company
0.09%
235,889
$11,823,000 30 Sep 2017
13F
GAM Holding AG
13F
Company
0.09%
225,000
$11,277,000 30 Sep 2017
13F
BNP PARIBAS FINANCIAL MARKETS
13F
Company
0.08%
201,476
$10,097,977 30 Sep 2017
13F
AMUNDI ASSET MANAGEMENT US, INC.
13F
Company
0.07%
189,899
$9,517,000 30 Sep 2017
13F
MUFG Securities EMEA plc
13F
Company
0.07%
180,000
$9,022,000 30 Sep 2017
13F
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
0.07%
176,611
$8,851,000 30 Sep 2017
13F
Invesco Ltd.
13F
Company
0.07%
174,097
$8,726,000 30 Sep 2017
13F
CREDIT AGRICOLE S A
13F
Individual
0.06%
157,900
$7,914,000 30 Sep 2017
13F
Iguana Healthcare Management, LLC
13F
Company
0.06%
150,000
$7,518,000 30 Sep 2017
13F
TEACHERS ADVISORS, LLC
13F
Company
0.06%
142,981
$7,166,000 30 Sep 2017
13F
Quantitative Investment Management, LLC
13F
Company
0.05%
123,600
$6,194,000 30 Sep 2017
13F
DEUTSCHE BANK AG\
13F
Company
0.05%
117,987
$5,912,000 30 Sep 2017
13F
Bank of New York Mellon Corp
13F
Company
0.04%
115,372
$5,783,000 30 Sep 2017
13F
UBS Group AG
13F
Company
0.04%
104,191
$5,223,000 30 Sep 2017
13F
AQR CAPITAL MANAGEMENT LLC
13F
Company
0.04%
103,726
$5,199,000 30 Sep 2017
13F
Informed Momentum Co LLC
13F
Company
0.04%
92,899
$4,656,000 30 Sep 2017
13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
13F
Company
0.04%
91,843
$4,604,000 30 Sep 2017
13F
VOLORIDGE INVESTMENT MANAGEMENT, LLC
13F
Company
0.04%
91,480
$4,585,000 30 Sep 2017
13F
DIMENSIONAL FUND ADVISORS LP
13F
Company
0.04%
90,750
$4,548,000 30 Sep 2017
13F
SABBY MANAGEMENT, LLC
13F
Company
0.03%
83,357
$4,178,000 30 Sep 2017
13F
S.c.a. Candriam
13F
Individual
0.03%
80,000
$4,010,000 30 Sep 2017
13F
PRICE T ROWE ASSOCIATES INC /MD/
13F
Company
0.03%
78,364
$3,928,000 30 Sep 2017
13F
BAILARD, INC.
13F
Company
0.02%
63,300
$3,173,000 30 Sep 2017
13F
JPMORGAN CHASE & CO
13F
Company
0.02%
61,800
$3,087,000 30 Sep 2017
13F
CITADEL ADVISORS LLC
13F
Company
0.02%
58,332
$2,924,000 30 Sep 2017
13F
GUGGENHEIM CAPITAL LLC
13F
Company
0.02%
55,095
$2,761,000 30 Sep 2017
13F
COLUMBUS CIRCLE INVESTORS
13F
Company
0.02%
51,997
$2,606,000 30 Sep 2017
13F
PARAMETRIC PORTFOLIO ASSOCIATES LLC
13F
Company
0.02%
49,335
$2,473,000 30 Sep 2017
13F

Institutional Holders of Esperion Therapeutics, Inc. - COM (ESPR) as of Q4 2017

As of 31 Dec 2017, Esperion Therapeutics, Inc. - COM (ESPR) was held by 163 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 24,011,278 shares. The largest 10 holders included BB BIOTECH AG, Meditor Group Ltd, Pentwater Capital Management LP, BlackRock Inc., FMR LLC, STATE STREET CORP, CREDIT SUISSE AG/, Vanguard Group Inc, Partner Fund Management, L.P., and Boxer Capital, LLC. This page lists 163 institutional shareholders reporting positions in this security for the Q4 2017 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q4 2017 vs Q3 2017 Across Filers

Q3 2017 holders
150
Q4 2017 holders
163
Holder diff
13
Investor Q3 2017 Shares Q4 2017 Shares Share Diff Share Chg % Q3 2017 Value $ Q4 2017 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .